Pfizer raises 2026 forecasts as Eliquis and cancer drugs offset falling Covid sales
Newer products are filling the revenue gap left by declining demand for Pfizer's Covid franchise.
Read at Reuters →Full coverage · 14 outlets
- Reuters · lead
- MedWatchPfizer lifts forecast as newer drugs offset falling Covid sales
- BloombergPfizer Raises Revenue Forecast, Extending Pharma Windfall
- CNBCPfizer hikes full-year outlook on new product growth, taps company veteran as new CFO
- Fierce PharmaPfizer delivers Q3 beat as post-COVID comeback gains momentum
- Business WirePfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
- The Pharma LetterPfizer raises 2026 revenue guidance as new products offset COVID-19 decline
- BNN BloombergPfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 results
- Crain's New YorkPfizer raises revenue forecast, extending pharma windfall
- Stock TitanPfizer Earnings Show Its Newer Medicines Selling 32% More
- The Edge MalaysiaPfizer raises 2026 forecast, extending pharma windfall
- Central Oregon DailyPfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat
- Pulse 2.0Pfizer: Raises 2026 Revenue Guidance By $500 Million As Non-COVID Products Outperform By $1.5 Billion
- The Globe and MailPFE Beats Q3 Earnings & Sales Estimates, Raises 2026 Guidance